Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Non-Culprit Vessel Angioplasty in the Elderly: Choosing the Right Cases Is Important

This large analysis found no benefit at a 1-year follow-up to angioplasty of non-culprit vessels in elderly patients admitted with ST-segment elevation myocardial infarction.

Angioplastia a vasos no culpables en añosos: la necesidad de elegir bien los casos

The COMPLETE study was presented at the European Society of Cardiology 2019 Congress (and simultaneously published in NEJM) with evidence that seemed to leave no doubt regarding this issue. However, new research and sub-studies from the COMPLETE study conducted in the last two years have dimmed such certainty.

This research analyzed all patients >65 years old with multivessel disease admitted with ST-segment elevation myocardial infarction between 2009 and 2017. All procedures performed on other vessels within 45 days of infarction were defined as “non-culprit vessel angioplasty.”

The primary endpoint was a composite of death, infarction, and revascularization conducted between 45 days and a year after infarction.

About 56,332 patients were admitted to 1102 institutions. Of all patients, 37.7% underwent angioplasty in other vessels within 4 days of the index angioplasty for the infarction.

In a first analysis of raw data, complete revascularization was superior, but this effect was diluted after adjusting for multiple confounding variables.

Ultimately, non-culprit vessel angioplasty did not show a significant difference compared with primary angioplasty alone (p = 0.46) in this population >65 years.


Read also: ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease.


Despite the multiple statistical adjustments made by the authors, this analysis is not without weaknesses (complete revascularization was left to operator’s discretion, the 45-day cut-off is arbitrary, among others).

Conclusion

In this large analysis with over 50,000 patients, no benefit could be found in performing multivessel angioplasty in elderly patients admitted with ST-segment elevation myocardial infarction. The benefit observed in large randomized studies may not be transferable to older patients and more complex decisions.

Original Title: Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project.

Reference: Eric A Secemsky et al. Circ Cardiovasc Interv. 2021 Aug;14(8):e010323. doi: 10.1161/CIRCINTERVENTIONS.120.010323.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...